ST-segment elevation myocardial infarction (STEMI)

Join Vijay Kunadian and Salvatore Brugaletta as they talk about the latest ESC guidelines for MINOCA (Myocardial Infarction with Non-Obstructive Coronary Arteries). Together, they review the crucial aspects of identifying MINOCA patients, how to diagnose them effectively using available diagnostic tools and the importance of post-treatment...

In this EuroPCR 2024 interview, Alaide Chieffo and Gabor Toth discuss mechanical circulatory support in cardiogenic shock and myocardial infarction. They address the ECLS-SHOCK trial's lack of benefit from prophylactic ECMO, stressing improved patient selection and timing. They contrast this with the DanGer Shock study, where...

REDUCE-AMI is a multicentre, registry-based, prospective open-label parallel-group randomised clinical trial evaluating the benefit of beta-blocker treatment in patients with acute MI and an ejection fraction >50% treated with a contemporary reperfusion strategy.

Nicola Ryan and Ali Nazmi Calik provide their take on the results which were presented...

Mirvat Alasnag interviews Jacob Eifer Møller about the results of the DANGER-shock Trial which he presented at the ACC.24 in Atlanta.

Results show that the implantation of microaxial flow pump post-heart attack significantly boosts survival in patients with STEMI-related cardiogenic shock, though with increased complications. The trial's positive...

Elad Asher provides his take on the ULTIMATE-DAPT Trial results which Gregg W Stone presented at ACC.24 in Atlanta.

Live updates on a selection of major Late Breaking Clinical Trials of interest in interventional cardiology presented at the American College of Cardiology 2024 Scientific Sessions #ACC24

Nicola Ryan provides her take on the FULL REVASC trial which was presented at ACC.24 in Atlanta and published Simultaneously in NEJM.

The FULL REVASC trial is a multicentre registry-based randomised control trial comparing FFR-guided complete revascularisation of non-culprit lesions versus culprit lesion PCI alone in patients presenting...

Marco Spagnolo and Daniele Giacoppo report the main results of the IVUS-ACS trial presented by Shao-Liang Chen, from the Nanjing First Hospital, Nanjing Medical University, Nanjing, in a Featured Clinical Research session at ACC.24 in Atlanta and simultaneously published in The Lancet.(1)

Ali Nazmi Calik provides his take on the results of the PREVENT trial presented at ACC.24 in Atlanta.

Observe this TAVI case featuring pulseless electrical activity due to an unforeseen acute occlusion of the right coronary artery, and discover the strategies employed to address and resolve this critical complication.